Related Experiment Videos
Recent advances in recombinant adeno-associated virus vector production
1Children's Hospital Research Foundation, Children's Hospital, Columbus, Ohio 43205, USA. clarkr@pediatrics.ohio-state.edu
Kidney International
|February 14, 2002
Summary
Adeno-associated virus (AAV) vectors show promise for gene therapy due to efficient transduction of cells. Recent advancements now enable large-scale production of these recombinant AAV (rAAV) vectors for clinical applications.
Area of Science:
- Biotechnology
- Gene Therapy
- Virology
Background:
- Adeno-associated virus (AAV) is a replication-defective parvovirus utilized as a gene transfer vector.
- Recombinant AAV (rAAV) vectors are being developed for treating various human diseases.
- rAAV vectors efficiently transduce postmitotic cells, leading to sustained gene expression.
Purpose of the Study:
- To address the challenge of insufficient production quantities for adeno-associated virus (AAV) vectors.
- To highlight recent technological advancements in AAV vector production, purification, and titration.
Main Methods:
- Focus on technological advances in vector production.
- Improvements in purification techniques.
- Enhanced titration methods for accurate quantification.
Main Results:
- Significant increases in production capacity (>10-fold) achieved.
- Production levels now exceed 10^4 particles/cell.
- Overcoming previous limitations in generating sufficient quantities for trials.
Conclusions:
- Recent technological progress has resolved major obstacles in rAAV vector production.
- Sufficient quantities of rAAV vectors are now attainable for widespread clinical use.
- This advancement facilitates the broader application of AAV-based gene therapy.